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ABSTRACT 
 
A simple, precise, accurate, sensitive  bioanalytical  method has been 
developed and validated for  pirfenidone by RP-HPLC method and its 
application to the determination of drug food interaction study in wister 
rats. The separation and quantization of Pirfenidone was achieved on a 
Phenomenex C-18 RP column (25 cm x 4.6 mm, 5µm ID) using the mobile 
phase in gradient mode constituting of eluant A  HPLC grade water 
(adjusted to pH 3.5) and eluant B 20% acetonitrile and 15% of methanol in 
the ratio of 60: 40(A:B) at a flow rate of  1mL min
-1
. Eluted components 
were detected at 324 nm. The method showed good linearity for 
Pirfenidone in the range of 50–250ng mL-1,  Y=54.97x - 349.5and 
correlation coefficient R
2
 was 0.998 respectively. The limit of quantitation 
(LOQ) and limit of detection (LOD) were found to be 12 and 20 ng mL-1 
respectively. The developed method shows good accuracy and precision. 
For bioanalytical study, parameters like Cmax, Tmax, AUC 0-t, AUC 0-∞, Keli  
and T1/2 were compared by statistical analysis. The  statistical analysis 
indicated  that there is no significant difference  in the pharmacokinetic 
profile of pirfenidone before and after food. This method was successfully 
applied to the bioavailability study of Pirfenidone. 
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CHAPTER- 1 
INTRODUCTION
 1-14 
Pharmaceutical analysis is a specialised branch of chemistry that deals with 
the identification of compounds and mixtures (qualitative analysis) or the 
determination of the proportion of the constituents (quantitative analysis). It plays an 
imperative role in the quality assurance and quality control of the bulk drugs and their 
formulations. Drug analysis reveals identification, characterization and determination 
of the drugs in mixtures like dosage forms and biological fluids. 
The number of drugs introduced into the market has been rising at very hasty 
rate. These may be either new drug entities or partial structural modification of the 
existing drugs.   
Newer analytical methods are developed for these drugs because: 
 The official pharmacopoeia may not disclose an analytical procedure for the 
drugs or its combination. 
 Analytical methods may not be available for the drug combination due to 
interference caused by excipients. 
 Analytical methods for the quantification of drug or drug combination from 
biological fluids may not be available. 
The recently developed analytical methods have their significance in different 
fields like  
 Research and development centre 
 Quality control department 
 Approved testing laboratory 
 Chemical analysis laboratory 
The new pharmaceutical product has its origin as a new molecule, from the 
research and development department of   a pharmaceutical industry. In every 
developmental stage through various departments, the product should meet the 
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prescribed standards and quality. It is very essential to assure that the drug will 
comply with the specific standards throughout the shelf life. 
The discovery and development of a new drug costs approximately $1 billion 
and it may take around 10 years for a drug to reach the market. This is a process of 
generating compounds and evaluating all their properties to establish the viability of 
selecting a new chemical entity (NCE) to develop into a safe and efficacious drug. 
Experimental pharmacokinetics (PK) data from laboratory animals in the nonclinical 
stage is critical in evaluating a drug candidate prior to the test in the clinical trials, for 
safety and efficacy evaluation. A key factor in pharmacokinetics is the plasma or 
tissue concentration of the new drug after its administration to the laboratory animals. 
Therefore, developing a precise and rapid analytical method for measuring the 
concentration of a compound in plasma or tissue is the ﬁrst step to yield the PK of a 
compound. To minimize the resource expenditures, an appropriate level of 
bioanalytical support is needed for a drug candidate. 
1.1   IMPORTANCE   OF BIOANALYTICAL METHODS:  
The accurate determination of the concentration of a drug candidate and its 
resulting metabolites in biological fluids plays an indispensable role  in the drug 
discovery, preclinical and clinical development programs. The drug concentration 
values determined are used to calculate the pharmacokinetic properties of the 
candidate drug molecules. In discovery these properties are used to select the most 
promising candidate compound, from a library or parallel synthesis experiment, to be 
carried ahead into development. 
In development the pharmacokinetic values derived from both Drug 
Metabolism And  Pharmacokinetic Environment( DMPK) and safety assessment 
studies are used to provide evidence of the dosed compound exposure, evaluate the 
effect of increased drug dosing on compound exposure and estimate the appropriate 
dose to be used in the initial human clinical trials. The metabolism of the compound 
in mammalian species, such as rat, dog and mouse need to be extensively studied and 
accurately defined in this scenario.  
             Bioavailability study of a drug product is an important constituent in support 
of orally administered drug products in Investigational New Drug application (INDs), 
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New Drug Applications (NDAs), Abbrivated New Drug Applications (ANDAs) and 
their supplements.  
Pharmacokinetics is the quantitative study of drug movement in, through and 
out of the body. The intensity of the response is related to the concentration of the 
drug at the site of action, which in turn is dependent on its pharmacokinetic 
properties. 
             After oral administration the drug passes through the GIT and enters the 
systemic circulation undergoes metabolism, ultimately it is excreted as such or in the 
form of its metabolites. The studies on biological fluids disclose the information 
relating the quantity of drugs and their metabolites in biological fluids. When 
concentration of drug in biological matrix is known, then pharmacokinetic parameters 
are calculated from that.  
            Bioavailability is defined as the rate and extend to which the active ingredient 
is absorbed from a drug product and becomes available at the site of action. 
Bioavailability of active pharmaceutical ingredient should be known and 
reproducible. 
In bio analytical method, the qualitative and quantitative analysis of drug 
substance and metabolites in biological fluids or tissues are carried out. The assay 
methods should be precise, accurate and sensitive enough to estimate the drug and 
metabolite concentration in the biological fluid, for a period of about five elimination 
half-lives following oral drug administration. 
The bioavailability studies should be designed so as to reduce the possible 
source of variation. The conditions of the study should be standardised as far as 
possible. 
1.2   PHARMACOKINETIC TERMS: 
Cmax 
This is the maximum drug concentration that achieved in systemic circulation 
following drug administration. 
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Cmin                                                                                                                                                                   
 This is the minimum drug concentration achieved in systemic circulation    
following multiple dosing steady state level. 
Cpd 
This is the predose concentration determined before a dose is given at steady 
state. 
Tmax 
This is the time required to achieve the maximum drug concentration in 
systemic circulation. 
AUC0-t 
Area under plasma concentration-time curve from 0h to last quantifiable       
concentration to be calculated using the trapezoidal rule. 
AUC0-∞ 
Area under plasma concentration-time curve from 0h to infinity to be 
calculates the sum of AUC0-t plus the ratio of the last measurable concentration to the 
elimination rate constant. 
AUC0-                                                                                                                                    
Area under plasma concentration-time curve over one dosing interval following single 
dose for modified dose product. 
AUC0 (ss) 
Area under plasma concentration-time curve over one dosing interval in 
multiple dose study at steady state. 
Keli 
Apparent first order terminal elimination rate constant calculated by a semi log 
plot of the plasma concentration versus time curve. 
T1/2 
Elimination half life of a drug was the time necessary to reduce the drug 
concentration in blood, plasma, or serum to one half after equilibrium is reached. 
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1.3   ANALYSIS OF DRUG IN BIOLOGICAL MEDIA: 
The most common samples obtained for bio analysis are blood, urine, and 
faeces, saliva, bile, breath and tissue. The nature of drug used in the study determines 
the choice of sampling media. Blood is mostly used in bio analytical methods for 
identification and quantitative analysis of drugs. Clinical analysis is done mainly on 
plasma and serum which containing less interfering substance than whole blood. 
1.4   EXTRACTION PROCEDURES FOR DRUGS FROM BIOLOGICAL 
SAMPLES: 
Various components may interfere in the detection of drug or its metabolite in 
biological media and make it complicated. The goal of every extraction process is 
rapid and effective isolation of compounds from an endogenous biological material by 
use of minimum amount of solvent. The extraction method determines the sensitivity 
and selectivity of the assay procedure. 
The main objectives of sample preparation prior to chromatographic 
separation are: 
1. The dissolution of analyte in suitable solvent. 
2. Removal of interfering compound as possible. 
3. Pre-concentration of the analyte. 
 
Depending on the type of biological matrix, the extraction methods can be varied. 
 
The types of extraction methods are: 
 Protein precipitation method. 
 Liquid-liquid extraction method.(LLE) 
 Solid-phase extraction method.(SPE) 
 Dehydration method.  
 Turbulent Flow Chromatography (TFC) 
 Hybrid extraction technique. 
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1.4.1 PROTEIN PRECIPITATION METHOD 
Protein precipitation method is very simple, economical and effortless than 
LLE and SPE. Precipitating agents or organic solvents are added to the biological 
fluid to remove protein by denaturation or precipitation. The precipitating agents are 
acids like trichloroacetic acid, perchloric acid or organic solvents like acetonitrile, 
methanol, ethanol, acetone etc.  The organic solvents used here should have good 
solubility of analyte and a property of protein precipitation. This method is suitable in 
clinical therapeutic drug monitoring and for HPLC method. Three methods of protein 
precipitation are  
 By changing the pH of the sample 
 By addition of organic solvents 
 Salt induced precipitation      
1.4.2 LIQUID –LIQUID EXTRACTION (LLE) 
Liquid- liquid extraction is a technique used to extract analytes from liquid 
matrices. Isolation of analyte from interferences is done by partitioning or distribution 
of the sample between two immiscible liquids or phases. Partitioning or distribution 
of a drug between two immiscible liquid phases can be expressed in terms of partition 
or distribution coefficient, called Partition coefficient. In LLE one phase is aqueous 
and other is organic solvent. For aqueous phase more hydrophilic compounds are 
preferred and for organic solvent more hydrophobic compounds are preferred. The 
two phases used in this method should be immiscible to each other. The solvent 
should have a low boiling point to facilitate removal at the end of extraction, and a 
low viscosity to facilitate mixing with the sample matrix. Selectivity is improved by 
choosing the least polar solvent in which the analyte is soluble. The commonly used 
extraction solvents are ethyl acetate, diethyl ether, hexane, dichloromethane etc. 
1.4.3 SOLID-PHASE EXTRACTION METHOD (SPE) 
Solid phase extraction is based on selective adsorption mechanism. It occurs 
between a solid phase and a liquid phase; either phase may initially contain the drug 
substance.  The solids that have been used in the extraction of drugs from liquid 
samples are XAD-2 resin, charcoal, alumina, silica gel, and aluminium silicate. This 
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method is also known as liquid solid extraction.  Liquid solid extraction is particularly 
suitable for polar compounds and amphoteric compounds that cannot be extracted 
easily from water. 
The hydrophobic portion of the solute that has little affinity for the water 
phase is preferentially adsorbed on the resin surface while the hydrophilic portion of 
the solute remains in the aqueous phase. The solid phase used here is plastic 
disposable column or cartridge which is packed with 0.1 to 0.5 gm of sorbent like 
reversed phase material (C-18silica) which has been bonded  to a hydrocarbon phases. 
In this method the liquid sample is added to the cartridge and from that eluent 
is collected. In this organic solvent consumption is very less and the collection of the 
analyte is easy. 
1.4.4 DEHYDRATION METHOD 
  Extracts from liquid-liquid extractions often contain water originating from 
the sample, so sample concentration or clean-up using columns cannot be done 
directly.  Thus, it is necessary to dehydrate the extract.  Dehydration is most 
commonly achieved by using anhydrous sodium sulphate.  Samples are dehydrated by 
adding the anhydrous sodium sulphate directly to the extract and then filtering the dry 
solvent solution, or passing the samples through a column or funnel packed with 
anhydrous sodium sulphate. 
1.4.5 TURBULENT FLOW CHROMATOGRAPHY (TFC) 
It allows on-line extraction of crude biological matrices. It has played an 
important role in facing all the challenges of bioanalysis. It successfully separate 
matrix interferences and enabling analysis and detection. The size exclusion 
properties of this eliminate the high molecular weight portion of the matrix, and the 
salts, while the stationary phase coating retains the analyte through the reverse-phase 
and anion-exchange column chemistry. This results in an on-line separation prior to 
an analytical separation. 
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1.4.6 HYBRID EXTRACTION TECHNIQUE 
Selective extraction of analyte by using the combination of two or more 
extraction techniques. This method is adopted to improve the specificity, detection 
limits and recovery.  
1.5 ANALYTICAL TECHNIQUES USED FOR THE QUANTITATIVE 
DETERMINATION OF DRUGS IN BIOLOGICAL FLUIDS:  
There are different types of methods for quantitative determination of drugs in 
biological fluids. These methods are selected according to the nature of biological 
fluid and the drug to be quantified. They are:  
a) Methods based on immunoassay procedure 
 Radioimmunoassay (RIA). 
 Enzyme-multiplied immunoassay technique. 
 Enzyme-linked immunosorbent assay (ELISA). 
b) Microbiological methods. 
c) Capillary electrophoresis. 
d) Chromatographic methods. 
 Gas chromatography (GC). 
 High performance liquid chromatography (HPLC). 
 Liquid chromatography-mass spectroscopy (LC-MS). 
 Gas chromatography –mass spectroscopy (GC-MS). 
 Scientiﬁcally qualiﬁed and properly maintained instruments should be used for the 
implementation of bio analytical methods in routine drug analysis. 
Chromatographic methods are mostly used for the estimation of drugs in 
biological samples. It is a separation technique used for the isolation of required 
analyte from a mixture by using mobile phase and stationary phase  
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1.6 ESTIMATION OF DRUGS IN BIOLOGICAL SAMPLE BY HPLC: 
The determination of low concentrations of active ingredients from complex 
mixtures like biological samples has become more obligatory.  Federal regulations 
have imposed strict limits on the type and concentrations of ingredients. Such 
requirements demands, rapid and unfailing analytical techniques that have separation 
and analysis steps combined in a single operation. 
             High performance liquid chromatography is one of the sophisticated methods 
for separation of samples from biological fluids. The principle of this technique is 
adsorption. In this, stationary phase is solid packing material in the column and 
mobile phase is liquid.  
The advantages of HPLC are: 
 Rapid  (analysis can be completed in 20 min or less) 
 Improved resolution (wide variety of stationary phase). 
 Precise and reproducible. 
 Uncomplicated recovery of sample, handling and maintenance. 
 Better sensitivity. (various detectors can be employed)  
 Calculations are done by integrator itself. 
 Perfect for substances of low volatility. 
 Reusable column. 
1.7 MODES OF HPLC: 
The modes in HPLC are: 
 Normal phase  
 Reverse phase 
 Ion pair chromatography 
  Ion exchange chromatography 
 Affinity chromatography  
 Size exclusion chromatography (gel permeation and gel filtration 
chromatography). 
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In normal phase mode chromatography, the stationary phase is polar and 
mobile phase is non-polar in nature. Because of the lower affinity towards the 
stationary phase, the non-polar compounds get eluted first and the polar compounds 
with higher affinity towards the stationary phase will eluted later. But most of the 
drugs are polar in nature and they elute slowly, so this mode is not appropriate in 
pharmaceutical industries. 
In reverse phase mode chromatography the stationary phase is non-polar and 
mobile phase is polar in nature. So, polar compounds elute faster due to their less 
affinity towards the stationary phase. As most of drugs are polar in nature this mode is 
more significant in pharmaceutical industries. In this stationary phase used is a non-
polar hydrophobic packing of octyl or octa-decyl group bonded with silica gel and 
mobile phase is a polar solvent. Thus it is used in the separation of the compound of 
interest in food, chemical, biological and pharmaceutical products. 
1.8 INSTRUMENTATION OF HPLC: 
The different parts in HPLC are: 
 Mobile  phase reservoir  
 Pumps  
 Injector  
 Column  
 Detector  
 Data system  
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Fig1:   Schematic diagram of HPLC 
1.8.1 MOBILE PHASE RESERVOIR:   
             It is used to store mobile phase. Mostly used type of solvent reservoir is glass 
bottle provided with special caps. In these glass bottles mobile phase selected is stored 
and for purging of this suitable gas is used. Purging is done in order to remove the 
dissolved air in the mobile phase, usually helium gas is used for purging. 
1.8.2 PUMPING SYSTEM: 
             HPLC pumping systems are required to deliver metered amounts of mobile 
phase at a constant flow rate expressed in millilitres per min (mL/min). Normal flow 
rates in HPLC are in 1 to 2mL/min range. Pumping systems that deliver solvent from 
one or more reservoirs are available. The tubing connections which are given to the 
pumps should also withstand the pressure developed in pumps (usually 400 to 600 
bars). It is necessary to have a proper degassing system or membrane filtering or 
purging with helium gas. The pressure in the pumps depends on the flow rate of the 
solvent used. So the pumping system in HPLC is more important to maintain the 
suitable pressure in the instrument. During the chromatographic experiment, a pump 
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can deliver a constant mobile phase composition (isocratic) or an increasing mobile 
phase composition (gradient). 
1.8.3 INJECTOR: 
               The sample solution is usually introduced into the flowing mobile phase at 
or near the head of the column using an injection system based on an injection valve 
design which can operate at high pressure. Such an injection system has a fixed –loop 
or a variable column device. Automatic devices for introducing samples like auto 
samplers or microprocessors are used. In HPLC, the liquid samples are directly 
injected and solid samples are dissolved in suitable solvent and then injected. Injector 
has two positions i.e. load position and inject position. The sample is injected into the 
injector in inject position and then, it is passed to the column. Typically the sample 
volumes are 5 to 20 µL. 
1.8.4 COLUMN:  
             Column acts as the heart of HPLC. HPLC columns are different types and are 
made up of stainless steel with length of 5, 10, 15 and 25 cm, diameter of 3, 5 or 
10µm particles and internal diameter of 4.6mm. Micro bore column are those which 
have internal diameter 2mm. The column and the mobile phase are maintained at 
constant temperature, usually at ambient temperature where most of the separations 
are carried out. Usage and maintenance of the column is done carefully. Mainly the 
columns are of two types: 
 Silica based type and Polymer type. 
Silica is basic ideal material in HPLC column. It has excellent physiochemical 
surface properties, mechanical stability and compatible with a wide range of organic 
solvents. Some silica based columns are C8, C18, C4, C13 and CN. 
1.8.5 DETECTOR: 
            Ultraviolet/visible (UV/vis) absorption spectrometers are the most commonly 
used detectors for pharmaceutical analysis. In specific cases fluorescence 
spectrophotometers, differential refracting meters, electro chemical detectors, light 
scattering detectors, mass spectrometers, or other special detectors may be used. If  an 
analyte possesses a chromophoric group that absorbs UV/visible radiation, the 
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UV/visible detector is the most appropriate because of its sensitivity and stability. 
Such a detector is not suitable for detecting analytes with very weak chromophores. 
              An alternative of the UV/visible type of detector, is the diode array detector 
which is becoming increasingly popular because of its ability to furnish detailed 
spectral information. This type of detector acquires absorbance data over a certain 
UV/visible range and can provide chromatograms at multiple, selectable wave 
lengths, together with spectra for the eluted peaks. In addition, the detector 
accompanying computer programs can be used to assess the spectral homogeneity of 
peaks, which may provide information on the chromatographic purity of the peaks. 
This can be especially useful in method development validation. 
1.8.6 DATA SYSTEM:   
             The electrical signal from the detector is analyzed by computer system. The 
data can be stored for   further use. The analysis options in these devices contains 
important features such as overlapping of peaks, resolution run parameters are 
present. Analytical reports can be customized to the needs of the analyst. It is used to 
determine the time of elution (retention time) of the sample components (qualitative 
analysis) and the amount of sample (quantitative analysis). 
1.9 MOBILE PHASES USED IN HPLC: 
In HPLC a broad variety of mobile phases can be used. According to the mode 
of HPLC mobile phase can be selected like polar nature or non-polar. Mobile phase 
selection depends on many factors like purity, sample solubility, chemical inertness, 
detector compatibility and low viscosity. Mostly organic solvents like acetonitrile, 
methanol, ethanol, formic acid etc are used. Sometimes these solvents mixed with 
water can also be used. These mobile phases should be selected according to the 
properties of drug to be estimated in HPLC, so its selection should be done cautiously. 
Based on the mobile phase only, the drug elutes and chromatogram of that drug 
comes properly. The pH of mobile phase has to be selected in such a way that the 
compounds are not ionized. 
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1.10 QUANTITATIVE ANALYSIS BY HPLC: 
Generally three methods are used for the quantitative analysis in HPLC. They 
are  
1) External standard method.  
2) Internal standard method. 
3) Standard addition method. 
 
1.10.1 EXTERNAL STANDARD METHOD: 
             In this method standard and sample peak area or height are directly compared. 
The external standard method can be done by using single standard or up to three 
different standard solutions. In this method standard and unknown sample are injected 
and then the concentration of unknown sample can be determined by plotting 
calibration curve graphically or by numerically using response factors. For good 
quantification in this method constant chromatographic conditions should be 
maintained for both standard and sample separation.  
1.10.2 INTERNAL STANDARD METHOD:   
In this method a known quantity of a compound is added to known amount of 
sample to give separate peaks, which compensate the loss of compound of interest 
during sample pre treatment. To overcome various analytical errors addition of 
internal standard is the commonly used method. The compound selected as internal 
standard should be completely separate from the sample and should not interfere it. In 
chromatographic analysis internal standard is added to the compound to be analyzed 
are desirable, if any loss of compound may occur during handling.  
In this way both internal standard and concentration of sample ratio remains 
constant regardless of amount of solution lost.  Any loss of compound of interest will 
be accompanied by the loss of an equivalent fraction of internal standard. The internal 
standard selected should have similar properties of that of the interested compound or 
any other compound with other properties also can be taken. In chromatographic 
analysis internal standards are frequently used. The internal standard used should be 
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added to sample before sample preparation and mix properly. By using response 
factor (Rf) concentration of sample can be known. 
SELECTION OF INTERNAL STANDARD: 
A compound added to a sample in known concentration to facilitate the 
qualitative identification and/or quantitative determination of the sample components, is 
known as internal standard. A compound will be selected based upon polarity and 
solubility, and chromatographed along with the standard drug. The peak of this 
compound should be symmetric and well resolved from the peak of the drug.  
 
REQUIREMENTS FOR A PROPER INTERNAL STANDARD: 
 Well resolved from the compound of interest. 
 Similar retention to the analyte. 
 Should not be in the original sample. 
 Should mimic the analyte in sample preparation steps. 
 Commercially available in high purity. 
 Stable and unreactive with sample or mobile phase. 
 Should have a similar detector response to the analyte. 
 
1.10.3 STANDARD ADDITION METHOD:  
In this method, a known amount of standard is added to the sample solution. 
By plotting calibration curve graphically the quantitative analysis is carried out. This 
method is used for sample which contains very small quantity of element to be 
analyzed. This method is used in trace analysis also. By adding the standard to sample 
solution the peak area is increased and concentration of sample will be computed by 
interpretation. 
1.11 VALIDATION OF BIO ANALYTICAL METHOD DEVELOPMENT: 
 Bio analytical method validation employed for the quantitative determination 
of drugs and their metabolites in biological fluids plays a significant role in the 
assessment and interpretation of bioavailability, bioequivalence, pharmacokinetic, and 
toxicokinetic study data. These studies generally support regulatory filings. The 
quality of these studies is directly related to the quality of the core bio analytical data. 
It is therefore important that the guiding principles for the validation of these 
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analytical methods are established and disseminated to the pharmaceutical 
community. 
 Analytical method validation is the series of demonstration that the analytical 
procedures are suitable for their intended use provide accurate test results that 
evaluate a product against its defined specification quality attributes .The U.S. Federal 
Register states “Validation data must be free to establish that the analytical procedures 
used in testing fulfil proper of successful reliability”. Any analytical test methods are 
expected to be used in a Quality Control background but they require an extra level of 
modification compared to research methods. 
Bio analytical method validation comprises all the procedures that display, a 
particular technique used for quantitative measurement of analytes in a given 
biological matrix, such as blood, plasma, serum, or urine, is reliable and reproducible 
for the intended use. 
 
Published methods of analysis are often customized to suit the requirements of 
the laboratory performing the assay. These modifications should be validated to 
ensure appropriate performance of the analytical method. When changes are made to 
a previously validated method, the analyst should implement decision that how much 
additional validation is necessary. During the course of a distinctive drug 
development program, a defined bioanalytical method undergoes many modifications. 
The evolutionary changes to support specific studies and different levels of validation 
demonstrate the validity of an assay’s performance.           
 
The fundamental parameters for this validation include accuracy, precision, 
selectivity, sensitivity, reproducibility, and stability. Each analytical method has its 
own characteristics which may vary from analyte to analyte. So, specific validation 
criteria are essential to be developed for each analyte. 
 
The process by which a specific bio analytical method is developed, validated 
and used in routine sample analysis can be divided into: 
1. Reference standard preparation for calibration curve 
2. Bio analytical method, development and establishment of assay procedure 
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3. Application of validated bio analytical method to routine drug analysis and 
acceptance criteria for the analytical group. 
 
1.12 NEED OF BIOANALYTICAL VALIDATION: 
Bioanalytical methods are complex and difficult to validate than the methods 
used for the quality control of drug products and drug substances because of the 
nature of the sample. This is because bioanalytical methods include more complex 
matrices, a large variety of interferences from metabolites, and comparatively low 
sample volumes. The bioanalytical data needs to be accurate and reliable because they 
are used for the crucial applications like the calculation of pharmacokinetic 
parameters that are critical in the review of the performance of a drug or a 
formulation. So bioanalytical methods need to be thoroughly validated. 
 
1.13 TYPES OF METHOD VALIDATION 
  Bioanalytical method validation (BMV) is done by three different levels. They 
are: 
 Full validation 
 Partial validation 
 Cross validation.  
1.13.1Full validation: 
Full validation is done when developing bio analytical method for first time 
for a new drug. When metabolites are added to an existing assay for quantification, 
then Full validation is done. 
1.13.2 Partial validation:   
It is the modification of already existing validated bio analytical method for 
which full validation is not necessary. Modifications done for bio analytical methods 
in which  small changes like change in species with matrix(from rat plasma to mouse 
plasma),change in matrix with in a species(from human urine to human 
plasma)change in laboratories or analysts, instruments, change in sampling process 
procedures, change in analytical method like changing detector.  
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1.13.3 Cross-validation: 
Cross-validation is a comparison of validation parameters when two or more 
bio analytical methods are used to generate data within the same study or across 
different studies. An originally validated bio analytical method serves as the reference 
and the revised bio analytical method is the comparator. 
 
When sample analyses within a single study are conducted at more than one 
site or more than one laboratory, cross-validation with spiked matrix standards and 
subject samples should be conducted at each site or laboratory to establish inter 
laboratory dependability. Cross-validation should also be considered when data 
generated using different analytical techniques in different studies are included in a 
regulatory submission. 
 
  
 
Fig 2:  Validated / Evaluated method 
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1.14FDA GUIDELINES FOR BIOANALYTICAL METHOD 
VALIDATION:   
For bio analytical method validation FDA had given some guidelines to help the 
scientists in the right track to develop an appropriately validated bio analytical 
method. They are:           
 Analyte stability in biological matrix at intended storage and operating 
conditions should be known. 
 Standard curve for matrix-based one should contain minimum 5 standards 
without including blank and it should cover the entire range of concentrations 
expected. 
 Essential parameters that are performed for acceptability of bio analytical 
method are precision, accuracy, selectivity, sensitivity and reproducibility. 
 Then the lower limit of quantification should serve as lowest concentration on 
the standard curve and that is not confused with limit of detection. 
 All these parameters are to be defined during the Full validation of a bio 
analytical method. 
 
1.15 VALIDATION PARAMETERS:  
 Different Types of Validation parameters are: 
 Precision  
 Accuracy 
 Specificity  Selectivity 
 Linearity  Range 
 Limit of Detection (LOD) 
 Limit of Quantification (LOQ) 
 Robustness 
 Ruggedness. 
 System Suitability 
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1.15.1 PRECISION:  
Precision is the closeness of individual measurements of the analyte when the 
procedure is applied repeatedly to multiple samplings of single homogenous sample 
under prescribed conditions. It is done at three levels such as repeatability, 
intermediate precision, and reproducibility. 
Acceptance Criteria: 
 Percentage Relative  deviation (%RSD)  NMT 1 % (Instrument precision) 
 (%RSD)  NMT -2% (Intra- assay precision) 
 
1.15.2 ACCURACY:  
It is the closeness of mean tests results obtained by the method to true 
concentration of analyte. Recovery studies are commonly used method for 
determination of accuracy. It is also named as trueness.  The usual range is being 10% 
above or below the expected range of claim. The % recovery was calculated using the 
formula, 
                                     100
)(
covRe%
bX
aba
ery

  
Where, 
 a –   Amount of drug present in sample 
 b – Amount of standard added to the sample 
    Acceptance Criteria: 
 In assay method, mean recovery will be 100%± 2% at each concentration 
between the ranges of 80-120% of the target concentration. 
 In impurity method, mean recovery will be 0.1% absolute of the theoretical 
concentration or 10% relative, whichever is greater for impurities between the 
ranges of 0.1-2.5 % (V/W). 
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1.15.3 LIMIT OF DETECTION (LOD): 
 The limit of detection is the lowest concentration of analyte in the sample 
which can be detected but not quantified under given experimental conditions. The 
lowest concentration which can be distinguished from the background noise with a 
certain degree of confidence is defined as limit of detection. Prepare the blank 
solution as per test method and inject six times into the chromatographic system. 
 
              Similarly prepare the linearity solution staring from lowest possible 
concentration of analyte to 150 % (or as per protocol) of target concentration and 
establish the linearity curve. 
 
 The detection limit (DL) may be expressed as: 
 
                 LOD   =       3.3 X Standard deviation of the response of the blank (σ)                                                                                                                                                                                               
                                                                         Slope  
   The slope shall be estimated from the calibration curve of the analyte. 
1.15.4 LIMIT OF QUANTIFICATION (LOQ): 
It is the lowest concentration of analyte in the sample that can be 
quantitatively determined with suitable accuracy and precision. 
In calibration curve it is the lowest concentration point. It is determined by 
accuracy, by the presence of background signal and by precision i.e. reproducibility of 
analyte in the method. 
  Acceptance Criteria: 
 In Pharmaceutical application, the LOQ is typically set at minimum 0.05% for 
active pharmaceutical ingredients. 
 LOQ defined as the lowest concentration providing a RSD of 5%. 
 LOQ should be at least 10% of the minimum effective concentration for 
clinical applications. 
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1.15.5 SPECIFICITY: 
 A method is said to be specific when it produces proper response only for a 
single analyte in the presence of components that may be expected to present, such as 
impurities, degradation products, matrix components, etc. It can be demonstrated by 
performing Placebo /blank interference and forced degradation studies. If the 
expected impurities or related substances are available, then they should be analyzed 
along with the analyte or sample to check the system suitability, retention factor, 
tailing factor and resolution etc. In this peak purity studies are done for specificity.  
 
1.15.6 LINEARITY:  
The linearity of an analytical method is its ability to evoke test results that are 
directly consider to the analyte concentration in samples within a given range. As per 
ICH definition “the ability to obtain test results which are directly proportional to the 
concentration of an analyte within given range is known as linearity of an analytical 
procedure”. By using correlation coefficient this can be tested. Using correlation 
coefficient is a benefit as it is a relationship between concentration and response data. 
In this data is analyzed by linear least square regression co-efficient and b of the 
linear equation,  
Y= a X + bBy  
the above equation regression r value can be known. For the method to be linear the r 
value should be close to1. Where Y is the measured output signal, X is the 
concentration of sample, a is the slope, b is the intercept. 
Acceptance criteria: 
 Coefficient of correlation should be NLT 0.99. 
1.15.7 ROBUSTNESS:   
 It is the measure of its capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides an indication of its reliability during 
normal usage. 
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1.15.8 RUGGEDNESS:  
According to the USP is “the degree of reproducibility of test results obtained 
by the analysis of the same samples under a variety of normal test conditions, such as 
different labs, different analysts, and different lots of reagents”. The following are the 
typical method parameters need to test during method validation:  
  Analyst-to-Analyst variability. 
  Column-to-Column variability. 
  On different days. 
  In different laboratories. 
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CHAPTER -2 
REVIEW OF LITERATURE 
  
Wang et al21 developed a high-performance liquid chromatographic method for the 
estimation of Pirfenidone and its key metabolites in rat plasma. The plasma proteins 
were precipitated with perchloric acid (10% v/v) and the supernatant  after 
centrifugation was  determined using high-performance liquid chromatography. A 
Lichrospher C-18 column with mobile phase containing acetonitrile-water containing 
0.2% acetic acid (23:77, v/v) was used. The flow-rate was 1mL min-1 and measured at 
310 nm by UV detector. The developed method was found to be linear at a range of 
0.15 to 76.67 µg mL-1. The method was validated for accuracy and precision and 
found to be satisfactory. The method was successfully applied for the 
pharmacokinetic study of Pirfenidone.  
 
Zhang et al22 developed a high-performance liquid chromatographic method for the 
determination of pirfenidone and its related substance. The development was carried 
out by using a Diamonsil C-18 column with mobile phase containing acetonitrile-
water containing 0.2% acetic acid (33∶67) at a flow rate of 1mL min-1. The detection 
wavelength was 310 nm. The linearity was found to be in a range of 34.38- 
171.91mgL-1. The linear equation was A=19205C+8017.3, R2 =0.9999. The RSD 
value was found to be 0.16%.  The developed HPLC method was simple, sensitive, 
specific, and accurate with excellent reproducibility and successfully applied for 
determination of pirfenidone.  
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CHAPTER-3 
AIM AND OBJECTIVE 
Determination of drug concentration in biological fluid is very much important 
in the field of bioavailability, bioequivalence, drug abuse, pharmacokinetics, 
toxicological studies, drug research and development, therapeutic drug monitoring 
and clinical studies. 
HPLC is the predominantly used separation technique for the analysis of 
biological fluids. It is a rapid and sensitive separation technique. The widespread 
acceptance of this separation method is due to its well-developed characteristics like 
ruggedness, specificity, linearity, precision and accuracy. 
Pirfenidone is a newer pyridine molecule with anti-inflammatory and anti 
fibrotic activity. It is used in the treatment of pulmonary fibrosis. It is a small non-
peptide molecule of low molecular weight 185.2 daltons.  It inhibits fibroblast 
proliferation & differentiation related to collagen synthesis. It also inhibits production 
& activity of TGF-β. It reduces production of fibronectin & connective tissue growth 
factor (CTGF).  
Pirfenidone  is not official in Indian Pharmacopoeia. 
From the extensive literature review, there were only two method found for 
the determination of pirfenidone.  The first method was   determination of related 
substance and another method was in biological sample. But this method suffers from 
some disadvantages like lack of internal standard and lower sensitivity.  
Since, there is no method reported to study the  effect of food on the 
pharmacokinetic profile of  Pirfenidone in rat plasma, there is a need to develop a 
more sensitive and cost effective method for the determination of pirfenidone in rat 
plasma and also to study the  effect of food in rat plasma. 
So the aim of present study is to develop a simple, rapid, more sensitive and 
cost effective liquid chromatographic method for the determination of pirfenidone in 
rat plasma and to study the effect of food on it.  
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CHAPTER-4 
PLAN OF WORK 
 
Bioanalytical  method development 
The present work is planned to divide into four phases 
 
Phase-I 
 
 Optimization and development of chromatographic 
conditions. 
 Selection of wavelength 
 Selection of initial separation conditions 
 Selection of mobile phase (pH, solvent strength, ratio and 
flow rate) 
 Nature of the stationary phase 
 Selection of internal standard 
 Selection of separation method and agent                                                  
Phase-II 
 Validation of the method.  
               The developed method were proposed to be validated using the various 
validation parameters such as, 
 Accuracy 
  Precision 
 Linearity  
 Limit of detection (LOD) / Limit of quantitation (LOQ) 
 Selectivity / Specificity 
 System suitability 
 Ruggedness / Robustness 
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Phase-III 
 The  amount of pirfenidone present in biological fluids were  proposed to be 
estimated, then analyzing pharmacokinetic study design and data handling. 
 
Phase -IV  
 Pharmacokinetic Study.  
              
The parameters of pharmacokinetic study is being proposed to be calculated as, 
 C max          – Maximum plasma concentration 
 T max          – Time of maximum plasma concentration 
 AUC (0-t)  – Area under plasma concentrations time curve 
                             0 to 12hrs. 
 AUC (0-∞) – Area under plasma concentrations time curve  
                                   0 to ∞ hrs  
 T ½            – Elimination  half life 
 K Eli            – Elimination constant 
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CHAPTER -5 
DRUG PROFILE
21,22
 
 
      Drug name      :              Pirfenidone  
 
5.1 CHEMICAL PROFILE: 
Chemical name            :  5-Methyl-1-phenylpyridin-2-one 
 Molecular formula      :  C12H11NO  
Molecular weight         :  185.2  
Category                       :  Antifibrotic and anti inflammatory agent 
Description                   :  White or almost white, hygroscopic powder 
Solubility                      :  Soluble in methanol, water and Di methyl sulfoxide 
 
Structure                       :  
           
 
Fig 3: Structure of Pirfenidone 
 
5.2 PHARMACOLOGICAL PROFILE:  
MECHANISM OF ACTION: 
          Pirfenidone is a pyridine molecule with anti-inflammatory and ant fibrotic 
activity. It is used in the treatment of pulmonary fibrosis. Pirfenidone inhibits the 
fibroblast proliferation and differentiation related collagen synthesis. It inhibits the 
production and activity of TGF-β, a cytokine that stimulates collagen synthesis and 
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inhibits its degradation. It reduces the production of other mediators of fibrogenesis, 
such as fibronectin and connective tissue growth factor (CTGF). 
 
PHARMACOKINETIC DATA 
 
   Half life                     : 2 - 2.5hrs 
   Excretion                   : Renal  
   Routes                       : Oral  
 
ADVERSE REACTIONS: 
            The most common adverse effects of pirfenidone are photosensitivity, loss of 
appetite (anorexia), stomach discomfort and nausea and elevated gamma glutamyl 
transpeptidase levels, AST (SGOT) and ALT (SGPT) levels. 
It may also lead to renal impairment and hepatic dysfunctions. 
 
 DOSAGE :      Available as 200mg and 400mg tablet 
 
CONTRAINDICATIONS:  
           Pirfenidone is contraindicated in patients with a history of hypersensitivity to 
the drug component. 
DRUG INTERACTIONS: 
        Pirfenidone clearance is reduced with co-administration of fluvoxamine, 
which inhibits CYP1A2 and several other CYP isoforms. Strong CYP1A2 inhibitors 
should therefore be used with caution in patients receiving pirfenidone due to 
potential for reduced clearance. Pirfenidone clearance is significantly higher in 
cigarette smokers than non-smokers, presumably due to higher CYP1A2 enzyme 
activity in smokers. 
INDICATIONS: 
Pirfenidone is indicated for the treatment of Idiopathic pulmonary fibrosis 
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CHAPTER-6 
METHODOLOGY 
6.1 MATERIALS AND INSTRUMENT USED:  
6.1.1 DRUG SAMPLE  &  STUDY PRODUCTS: 
Pirfenidone  standard was procured from Cipla Ltd, Himachal Pradesh, India. 
Test product    :      Pirfenex      (Pirfenidone 200mg Tablet)   
Company         :      Cipla Ltd. 
 
6.1.2 CHEMICALS AND SOLVENTS USED FOR ESTIMATION: 
• HPLC Water                - Qualigens, Mumbai, India  
• Acetonitrile              - Rankem, Mumbai, India.  
• Methanol               - Finar, Ahmadabad, India 
• Distilled water              - Double Distilled water.   
• Orthophosphoric acid       - SD fine chem. Ltd, Mumbai.  
 
6.1.3 INSTRUMENTS USED: 
• Elico pH meter LI 127. 
• Shimadzu LC-20 AT HPLC. 
• SPD-M20A Prominence diode array detector. 
• Shimadzu 1600 LC-UV Spectrophotometer. 
• Sonica ultrasonic cleaner.  
• Solvent filtration unit – Millipore. 
• Shimadzu electronic balance AY 220. 
• Ultra cooling centrifuge – Remi, India. 
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6.2 OPTIMIZATION OF CHROMATOGRAPHIC CONDITION FOR THE 
ESTIMATION OF PIRFENIDONE 
 
6.2.1SELECTION OF WAVELENGTH 
An UV spectrum of 10 µg mL-1 pirfenidone in water was recorded by 
scanning in the range of 200 nm to 400 nm. From the UV spectrum wavelength of 
324nm was selected.  At this wave length Pirfenidone showed maximum absorbance. 
6.2.2 SELECTION OF CHROMATOGRAPHIC METHOD 
Selection of proper chromatographic method depends on the nature of the 
sample or its properties like ionic/ionisable/neutral character, its molecular weight and 
solubility. The drug selected for the present study was polar in nature hence, reverse 
phase HPLC or ion-pair or ion–exchange chromatography method may be used. 
Because of its simplicity and appropriateness for initial separations reverse phase 
HPLC method was selected. 
 
6.2.3 INITIAL CHROMATOGRAPHIC CONDITIONS FOR SEPARATION  
Standard solution:  10µg mL-1 of pirfenidone solution was prepared in 
HPLC grade water. 
Equipment: 
System          :       Shimadzu gradient HPLC 
Pump            :        LC – 20AT prominence solvent   
                                                 delivery system 
Detector        :       SPD-M20A Prominence Diode array  
                                                  detector 
Injector         :       Rheodyne 7725i with 20µl loop 
 
Chromatographic conditions 1: 
         Stationary phase     : Phenomenex C-18 column (25 cm x 4.6 mm, 5µm ID) 
         Mobile phase          : Solvent A–water  
                              Solvent B-Acetonitrile                           
        Solvent ratio            :  50:50(A: B) 
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        Wavelength of detection    :           324nm. 
         Flow rate                          :           1.0mL min-1. 
         Sample size                      :            20µL.  
         Needle wash                     :            HPLC grade water. 
         Temperature                :            Room temperature (250C) 
 
At the above chromatographic conditions Pirfenidone was eluted at the 
retention time of  2.8 min. The peak observed was broad and asymmetric, thus not 
selected for further studies. 
 
 Chromatographic condition 2:  
          Stationary phase                    :    Phenomenex C-18 Column(25 cm x 4.6 mm,  
  5µm ID) 
           Mobile phase                     :    Solvent A–water pH 5.5   
                                                       (adjusted with orthophosphoric acid)  
                                  Solvent B-  Acetonitrile                       
           Solvent ratio                :     55:45  (A: B)          
          Wavelength of detection   :     324nm. 
           Flow rate                         :     1.0mL min-1. 
           Sample size                      :      20µL.  
           Needle wash                    :      HPLC grade water. 
          Temperature                 :     Room temperature (250C) 
Pirfenidone was eluted at retention time of 3.1 min with peak fronting, hence 
not selected for further method development. 
          
Chromatographic condition 3: 
   
Stationary phase                :   Phenomenex C-18 Colum(25 cm x 4.6 mm,  
5µm ID)  
            Mobile phase                     :   Solvent A–water pH 4.5  
                                                     (adjusted with orthophosphoric acid)  
                                 Solvent B- Methanol: Acetonitrile (10:25)                        
 Solvent ratio                   :    50:50     (A: B) 
            Wavelength of detection :   324nm. 
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Flow rate                              :   1.0mL min-1. 
Sample size                           :   20µL.  
Needle wash                         :   HPLC grade water. 
Temperature                     :   Room temperature (250C) 
 
Pirfenidone was eluted at retention time of 3.7 min with peak tailing and no 
peak was observed for internal standard. 
     
Chromatographic condition 4: 
   
Stationary phase                  :    Phenomenex C-18 Colum (25 cm x 4.6 mm,  
   5µm ID)  
            Mobile phase                       :   Solvent A–water pH 3.5  
                                                        (adjusted with orthophosphoric acid)  
                                   Solvent B- Methanol: Acetonitrile (15:20)                        
 Solvent ratio                     :   55:45     (A: B) 
            Wavelength of detection   :   324nm. 
Flow rate                           :   1.0mL min-1. 
Sample size                        :   20µL.  
Needle wash                      :   HPLC grade water. 
Temperature                  :   Room temperature (250C) 
 
Pirfenidone was eluted at retention time of 4.7 min with peak tailing, hence 
not selected for further method development.  
 
Chromatographic condition 5: 
 
Stationary phase                :   Phenomenex C-18 Column (25 cm x 4.6 mm,     
           5µm ID)  
             Mobile phase                    :   Solvent A–water pH 3.5  
                                                     (adjusted with orthophosphoric acid)  
                                Solvent B- Methanol: Acetonitrile (15:20)                        
Solvent ratio                   :    60:40     (A: B) 
          Wavelength of detection  :    324nm. 
Flow rate                         :   1.0mL min-1. 
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Sample size                      :   20µL.  
Needle wash                    :   HPLC grade water. 
Temperature                :   Room temperature (250C)  
 
Pirfenidone was eluted at 6.5min and internal standard at 4.5min with perfect 
peak properties, hence the above chromatographic condition was selected for further 
studies.  
      
6.24 Effect of pH 
 Using 20% of acetonitrile, 15% of methanol and water of different pH ranging 
from 3.5, 4.5, 5.5 at 324nm, the standard solution was runned up to 20 min at a flow 
rate of 1.0 mL min-1. The retention time of pirfenidone was 6.5, 4.7, 3.7 minutes 
respectively. The chromatogram obtained for pH 3.5 was symmetrical in shape, so for 
the present study, pH of 3.5 was selected. 
6.2.5 Effect of ratio of mobile phase 
Methanol,acetonitrile and water  with 50:50, 45:55 and 40:60 (B:A) ratios 
were used as the mobile phase. At 50:50 and 45:55 ratios the peaks  were asymmetric. 
At 40:60 (B:A) ratio, symmetric peaks were eluted at 6.5 min and 4.5 min for 
pirfenidone and internal standard (tinidazole) respectively. Thus for the present study 
40:60 ratio of methanol(15%), acetonitrile(20%)  and water was selected as the 
mobile phase.  
6.2.6 Effect of flow rate   
Chromatograms were recorded at a flow rate of 0.5, 1.0 and 1.5mL min-1 with 
the mobile phase ratio at (40:60 v/v) Methanol (15%), acetonitrile (20%): water (pH 
3.5). At flow rate of 1.0mL min-1, the peaks were sharp and separated with good 
resolution. Hence, flow rate of 1mL min-1 was kept constant for the present analysis. 
 
6.2.7 SELECTION OF INTERNAL STANDARD 
A known concentration of Tinidazole, geftinib and tinofovir were selected and 
chromatographed along with the standard drug. The selection was based upon polarity 
and solubility. The elution time of tinidazole was 4.5 min. The peak of tinidazole was 
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symmetric and well resolved from the peak of the pirfenidone. Hence, for the present 
study tinidazole was selected as the internal standard.  
6.2.8 Fixed chromatographic conditions  
The following chromatographic conditions were used for the estimation of 
pirfenidone. 
       Stationary phase   :  Phenomenex C-18 Column (25 cm x 4.6 mm, 5µm ID) 
        Mobile phase          :         Solvent A- Water pH 3.5 (adjusted with  
orthophosphoric acid) 
                                                 Solvent B -Methanol (15%) : Acetonitrile (20%) 
       Solvent ratio         :   60:40  (A: B) 
        Detection      :   324 nm 
        Flow rate      :   1.0 mL min-1 
       Sample size           :   20µL.  
       Temperature         :    Room temperature (250C) 
 
6.3 BIOANALYTICAL STUDY DESIGN 
             The study adheres to “Principles of Laboratory Animal Care” and is approved 
by the animal care committee IAEC/CPSEA-Institutional animal ethics /Committee 
for the purpose of control and supervision of experiments on animals 
(KMCRET/M.PHARM/13/2011-12). 
 
6.4 PHARMACOKINETIC STUDY DESIGN 
Animals for study : Rat 
             Healthy Wister rats (male) of weight 150-250 grams were taken and grouped. 
The rats were taken from KMCH college of pharmacy animal house, which were 
quarantined a week before. Rats are divided in to three groups, group A and group B 
and group C. Group A is control (4 rats), group B is set of fasted animals (10 rats) and 
group C is set of animals without fasting (10 rats).According to body weight of each 
animal, the dose of drug 30 mg/kg   was given through oral gavage. 
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6.5 PREPARATION OF STOCK SOLUTION   
Twenty tablets of pirfenidone were weighed and average weight was 
calculated. Weighed accurately tablet powder equivalent to 200mg and transferred 
into a 5 mL volumetric flask . Made up the volume with sufficient distilled water.  
6.6 SAMPLE WITHDRAWAL 
            According to the body weight of each animal the drug solution was given 
through oral gavage. Group (B) animals were kept fasted overnight. Blood samples 
were withdrawn at specified pre-determined time intervals from 0.5 to 6.0 h using 
retro orbital nerve puncture. The blood samples were immediately transferred to 
collection tubes containing Disodium EDTA and shaken well, centrifuged using ultra 
cooling micro centrifuge at  5000 rpm to separate plasma. The separated plasma 
samples were transferred to a labelled air tight sample tubes and kept in deep freezer 
for further analysis. 
6.7 SEPARATION METHOD 
6.7.1 PROTEIN PRECIPITATION METHOD  
             The separation method used here is protein precipitation. Precipitating agents 
(Diethyl ether and ethyl acetate) were added to the sample, and the precipitate was 
removed by centrifugation. The supernatant solution was collected and kept for 
evaporation. After complete evaporation sufficient amount of mobile phase was added 
to reconstitute the sample. The reconstituted sample was then injected into the HPLC 
column.  
              To 200µL of plasma sample, 200µL of standard drug solution, 200µL of 
internal standard,100µL of diethyl ether and 100µL of ethyl acetate were  added.  
Then it was centrifuged for 10 min at 5000 rpm. The same procedure was repeated 
with Acetonitrile and methanol and percentage recovery was calculated for all 
precipitating agents. According to percentage recovery, mixture of diethyl ether and 
ethyl acetate were chosen as the protein precipitating agents for further study. 
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6.8 ESTIMATION OF PIRFENIDONE IN PLASMA 
             For the estimation of pirfenidone in rat plasma, Shimadzu LC-20 HPLC 
system with the following chromatographic conditions was used: 
       Stationary phase         :  Phenomenex C-18  column (5µm,25cm×4.6mm ID) 
       Mobile phase              :   Solvent A- Water pH 3.5 (adjusted with orthophosphoric  
acid) 
                                                 Solvent B -Methanol (15%) : Acetonitrile (20%) 
      Solvent ratio                 :   60:40 % v/v 
      Detection wavelength  :  324nm 
      Flow rate                      :  1.0 mL min-1 
      Sample size                  :  20 µL 
      Needle wash                 :  water HPLC 
      Column temperature    :  Room temperature of above 25˚c 
6.9 PREPARATION OF STANDARD STOCK SOLUTION 
Stock solution of pirfenidone and internal standard 1000µg mL-1 were 
prepared separately using mobile phase. Weigh accurately 10mg of pirfenidone and 
internal standard into two separate 10mL volumetric flask and the volume was made 
up to 10 mL with the mobile phase.   
From the standard stock solution, 10µg mL-1 solution was prepared by diluting 
1mL to 100mL with mobile phase. 1mL of the above solution was diluted to 10mL 
with mobile phase to get a concentration of 1µg mL-1. Further solutions were made 
from the above solution by diluting 0.5, 1.0, 1.5, 2.0 and 2.5mL standard solutions to 
10mL in a standard flask with mobile phase to get concentrations of 50, 100, 150, 200 
and 250ng mL-1 respectively. 
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6.10 PREPARATION OF STANDARD GRAPH 
 To 200µL of blank plasma, 100µL of working standard solution of pirfenidone 
was added to yield a final respective concentration as 50,100,150,200 and 250ng mL-1 
of pirfenidone in plasma. To each calibration standard 100 µL of 1000ng/mL of 
tinidazole (internal standard) solution was added and vortexed. To these calibration 
standards, 100µL of precipitating agent (mixture of ethyl acetate and diethyl ether) 
was added, and centrifuged for 15 min at 5000 rpm. After centrifugation the clear 
supernatant liquid was collected and kept for evaporation. After complete evaporation 
the residue was reconstituted with mobile phase. A volume of 20µL was injected into 
the HPLC column and chromatograms were recorded. Standard calibration graph was 
plotted using peak area of pirfenidone against its concentration. 
 
6.11 ESTIMATION OF PIRFENIDONE IN RAT PLASMA: 
To 200µL of plasma (collected from rat at predetermined time interval after 
drug administration), 100µL of internal standard solution and  100µL of precipitating 
agent (mixture of ethyl acetate and diethyl ether) were added and centrifuged for 15 
min at 5000 rpm. After centrifugation the clear supernatant liquid was collected and 
kept for evaporation. After complete evaporation it was reconstituted with mobile 
phase. A volume of 20µL was injected into the HPLC column with the optimized 
chromatographic conditions and chromatograms were recorded. 
The retention time of pirfenidone and the internal standard (Tinidazole) were 
6.5 and 4.5 min respectively.  
6.12VALIDATION OF THE METHOD: 
Validation is an important step to be carried out after method development. It 
is to ensure that the developed method was suitable for the intended purpose.  
 
6.12.1 ACCURACY:  
It is the closeness of mean tests results obtained by the method to true 
concentration of analyte. It is also named as trueness.  The usual range is being 10% 
above or below the expected range of claim.  
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            To 200µL of plasma, 100µL of  standard drug solution, 100µL of internal 
standard solution and  100µL of precipitating agent (mixture of ethyl acetate and 
diethyl ether ) were added and centrifuged for 15 min at 5000 rpm. After 
centrifugation, the clear supernatant liquid was collected and kept for evaporation. 
After complete evaporation residue was reconstituted with mobile phase. A quantity 
of 20µL was injected into the HPLC column and analysed. The absolute recovery of 
pirfenidone was estimated by comparing the response factor of the drug obtained from 
the plasma with that obtained from the direct injection of drug in mobile phase.  
 
The response factor obtained from an amount of the drug added to and 
extracted from the biological matrix, compare to the response factor obtained for the 
true concentration of the pure authentic standard is known as the recovery of a drug in 
an assay. 
Recovery studies were carried out for three levels at six times and the 
percentage recovery, mean standard deviation and coefficients of variation were 
calculated. 
  
6.12.2 PRECISION:  
Precision is the closeness of individual measurements of the analyte when the 
procedure is applied repeatedly to multiple samplings of single homogenous sample 
under prescribed conditions. Intraday and interday precision studies were conducted. 
 
The intraday precision was evaluated by analysis of plasma sample containing 
drug at three different concentration containing the internal standard using nine 
replicate determinations for three occasion were injected and chromatogram was 
recorded.  
The inter -day precision was similarly evaluated over a period of two week 
and the response factor and RSD were calculated, from that the mean concentration, 
standard deviation and % CV were calculated. 
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6.12.3 RECOVERY STUDIES: 
 The relative recovery of drug from plasma was calculated by comparing the 
readings of concentration obtained from the plasma containing drug to that of equal 
concentration from standard sample.  Recovery studies were carried out six times for 
sample concentration at three levels within the calibration curve. 
6.12.4 LINEARITY AND RANGE: 
The linearity of an analytical method is its ability to evoke test results that are 
directly consider to the analyte concentration in samples within a given range. 
Range is the interval between the upper and lower concentration of the analyte 
in the sample such that it should have a suitable level of precision, accuracy and 
linearity. 
Linearity and range were estimated by using calibration curve. By using 
calibration standards  prepared by spiking drug (Pirfenidone) and internal standard 
(Tinidazole) in plasma at different concentrations like 100 ng mL-1 to 1000 ng mL-1  
the calibration graph was plotted taking concentration of spiked plasma on x-axis and 
peak area on y-axis. The linearity is determined from 50% to 150% of the proposed 
concentration.   
6.12.5 LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTIFICATION 
(LOQ): 
 Using the calibration curve, the LOD and LOQ were determined. 
  Limit of quantitation is the concentration of substance in the sample that will 
give a signal-to-noise ratio of 10:1.  Limit of detection is the concentration that will 
give a signal-to-noise ratio of 3:1. The signal to noise ratio were performed by 
comparing measured signal of blank plasma sample with those of known low 
concentration of drug. 
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6.12.6 SPECIFICITY: 
 A method is said to be specific when it produces proper response only for a 
single analyte in the presence of components that may be expected to present, such as 
impurities, degradation products, matrix components, etc.  
 Diode array detector peak purity test is used to demonstrate specificity. The 
diode array spectrum of both standard and sample peak were recorded and compared. 
It can also be measured by absorbance ratio of drug peaks at two different levels. The 
retention time (Rt), resolution factor (Rs) and tailing (T) were noted for the peaks of 
pirfenidone. Peak purity study is done to prove that a developed method is specific for 
the drug of interest. 
6.12.7 STABILITY:  
For a reasonable time, the stability of sample, standard and reagent used in 
HPLC method is required to generate reproducible and reliable results. Stability of 
plasma sample spiked with drug were subjected to three freeze-thaw cycles, short 
term stability at room temperature for 3 hours and long term stability at –200C for 
four weeks. Stability of standard solution and internal standard were performed at 
room temperature for 6 h and under frozen condition for two weeks. The stability of 
this solution was studied by performing the experiment and looking for change in 
separation, retention and asymmetry of the peak which were then compared with the 
pattern of chromatogram of freshly prepared solutions. 
6.12.8 SELECTIVITY: 
The ability of analytical method to differentiate and quantify the analyte in the 
presence of other components in the sample is known as selectivity. The selectivity 
was established by two different methods  
Method I: Chromatograms of six blank plasma samples obtained from six different 
rats were compared with chromatogram obtained from standard solutions. 
Interferences due to endogenous plasma component on the retention times of the 
selected drugs and internal standard were tested. 
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Method ІІ: The peak purity test method using diode array detector is involved in this 
method. The PDA spectrum, UV spectrum, absorbance ratio curve and first derivative 
spectrum of the standard and sample peak was recorded using PDA detector and 
compared for the peak purity of drug. 
6.12.9 ROBUSTNESS: 
It is the measure of its capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides an indication of its reliability during 
normal usage. By changing the chromatographic conditions slightly, the robustness of 
the method was studied. The standard solutions were injected in these changed 
chromatographic conditions.  
 ± 1 % difference in the ratio of acetonitrile in the mobile phase. 
 ± 0.5 difference in units of pH of the buffer. 
 ± 1 % difference in flow rate of the mobile phase.  
 In these changed conditions the separation factor, retention time and peak 
symmetry was calculated. Deviation in results from original run should be less 
than 2%. 
 6.12.10 SYSTEM SUITABILITY STUDIES:  
 As part of qualifying instruments, performance of system suitability ensures 
that the system is operating properly at the time of analysis. System suitability checks 
are more appropriately used for chromatographic methods to ensure that the system is 
sufficiently sensitive, specific and reproducible for the current analytical run. 
 In system suitability studies certain parameters such as column efficiency, 
resolution, capacity factor were calculated, by repeated injection of standard 
solutions.  
Capacity factor (k’): It is measurement of sample molecule how good is retained by a 
column during separation. The ideal k value ranges from 2-10. 
                                                Capacity Factor (k') = V1 – V0 / V0 
Where, V1 is the retention volume at the apex of the peak (solute)   and V0 is 
the void volume of the system.
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Resolution (Rs): It is the difference between the retention times of two solutes 
divided by their average peak width. The ideal value of (Rs) is 1.5 
                                   Resolution (Rs) = Rt1 –Rt2 /0.5(W1-W2) 
Where, Rt1 and Rt2 are the retention times of component 1 and 2, respectively. 
Column Efficiency (N): It is measured by the number of theoretical plates per meter. 
For ideal good separation, column efficiency N value ranging from 5,000 to 100,000 
plates/meters. 
                            Column efficiency (N) = Rt2 / W2 
                 Where Rt is the retention time and W is the peak width. 
Peak asymmetry factor:  For better column performance it was calculated by the 
formula. When asymmetry factor of value 0.9 to 1.1 then it is achievable for a well 
packed column. 
                                        Peak asymmetry factor (As) = b / a 
Where a and b are the distances on either side of the peak midpoint. 
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6.13 CHROMATOGRAMS 
 
Fig4: HPLC chromatogram of Blank Plasma 
 
Fig 5: HPLC chromatogram of standard Pirfenidone 
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Fig 6: HPLC chromatogram of standard Pirfenidone  and Tinidazole 
 
 
Fig 7: HPLC chromatogram of   plasma spiked with  Pirfenidone 50 ng/mL and 
Tinidazole 1000ng/mL 
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Fig 8: HPLC chromatogram of   plasma spiked with  Pirfenidone 100 ng/mL and 
Tinidazole 1000ng/mL 
 
 
Fig 9: HPLC chromatogram of   plasma spiked with  Pirfenidone 150 ng/mL and 
Tinidazole 1000ng/mL 
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Fig 10: HPLC chromatogram of   plasma spiked with Pirfenidone 200 ng/mL and 
Tinidazole 1000ng/mL 
 
Fig 11: HPLC chromatogram of   plasma spiked with Pirfenidone 250 ng/mL and 
Tinidazole 1000ng/mL 
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Fig 12: HPLC Chromatogram of Pirfenidone after 0.0 min (Before food) and spiked 
internal standard Tinidazole 1000ng/mL 
 
 
 
Fig 13: HPLC Chromatogram of  Pirfenidone  after 30 min (Before food) and spiked 
internal standard  Tinidazole 1000ng/mL 
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Fig 14: HPLC Chromatogram of  Pirfenidone  after  1h (Before food) and spiked 
internal standard  Tinidazole 1000ng/mL 
 
 
Fig 15: HPLC Chromatogram of Pirfenidone  after 2h (Before food) and spiked 
internal standard  Tinidazole 1000ng/mL 
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Fig 16: HPLC Chromatogram of  Pirfenidone  after 4h (Before food) and spiked 
internal standard  Tinidazole 1000ng/mL 
 
Fig 17: HPLC Chromatogram of  Pirfenidone  after  6h (Before food) and spiked 
internal standard  Tinidazole 1000ng/mL 
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Fig 18: HPLC Chromatogram of  Pirfenidone  after 0.0 min (After  food) and spiked 
internal standard  Tinidazole 1000ng/mL 
 
 
 
Fig 19: HPLC Chromatogram of  Pirfenidone  after 30 min (After food) and spiked 
internal standard  Tinidazole1000ng/mL 
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Fig 20: HPLC Chromatogram of  Pirfenidone  after 1h (After food) and spiked 
internal standard  Tinidazole1000ng/mL 
 
 
 
Fig 21: HPLC Chromatogram of  Pirfenidone  after 2h (After food) and spiked 
internal standard  Tinidazole1000ng/mL 
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Fig 22: HPLC Chromatogram of  Pirfenidone  after 4h (After food) and spiked 
internal standard  Tinidazole1000ng/mL 
 
 
Fig 23: HPLC Chromatogram of  Pirfenidone  after 6h (After food) and spiked 
internal standard  Tinidazole1000ng/mL 
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Fig24:  Peak Profile of standard Pirfenidone 
 
 
 
 
 
Fig 25: Peak Purity of standard Pirfenidone 
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Fig26:  Peak Profile of plasma spiked Pirfenidone 
 
 
 
 
 
 
 
 
Fig 27: Peak Purity of plasma spiked Pirfenidone 
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CHAPTER-7 
RESULTS AND DISCUSSION 
 
Chromatographic Conditions: 
Mixture of ethyl acetate and diethyl ether was selected as good separating 
agent for pirfenidone, since it showed maximum recovery in comparison with 
acetonitrile and methanol (Table1). The chromatogram was recorded for the standard 
and plasma sample under developed chromatographic conditions. The retention time 
of pirfenidone and Tinidazole are 6.5 min and 4.5 min respectively. The 
chromatogram was well resolved without any interference from one another. 
Moreover  Peaks  not showed any tailing or fronting. The concentration of pirfenidone 
in rat plasma was determined from the calibration of the spiked plasma by regression 
analysis. It showed very good linearity in the range of 50-250ng/mL and the R
2
 value 
was found to be 0.998 (Fig.28). 
  
Table 1 Recovery study for extraction method 
 
Level 
Conc. of 
drug added 
(ng/ml) 
Amt. of drug recovered from plasma 
(ng/ml) 
% Recovery 
ACN Methanol 
Diethyl 
ether  and 
ethyl 
acetate 
mixture 
ACN 
Metha-
nol 
Diethyl 
ether  and 
ethyl acetate  
mixture 
Level –I 50 44.26 39.50 47.61 88.52 79.01 95.22 
Level –II 100 86.14 80.38 95.12 86.14 80.38 95.12 
Level –III 150 135.47 120.79 145.64 90.31 80.52 97.09 
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Fig28: Calibration curve for pirfenidone 
  
METHOD VALIDATION  
 Accuracy and precision:  
 Accuracy and precision studies were performed at two levels i.e. intra-day and 
inter-day. In this, present developed method showed good accuracy and precision. 
Accuracy ranges from 98.49% to 99.37% with the precision 6.43% to 7.67% in inter-
day method. In intra-day method the accuracy ranges from 98.64% to 99.33%   with 
the precision 5.64%   to 6.93 %.  The data obtained here, was found to be within 
limits as per ICH guidelines and method was accurate.  
Intra-day studies: In this plasma concentration of 50-250ng/mL were injected six 
times and mean peak area was calculated separately for each concentration and from 
that accuracy and precision percentage RSD values were calculated and shown in 
table 3.                                           
Inter-day studies: In this the plasma concentrations  of 50-250ng/mL were injected 
into HPLC six times in three different days and mean peak areas were calculated and 
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from that accuracy and precision  percentage RSD were calculated and shown in        
table  2.  
Acceptance criteria: The percentage RSD value should be less than 15% for 
bioanalytical study. 
Table 2    Accuracy and Precision Studies of pirfenidone (Inter day) 
 
Si.No 
Conc. of       
Drug (ng/ml) 
Mean* Peak 
Area 
Accuracy 
(%) 
Precision 
(%) 
1. 50 2359 99.19 6.65 
2. 100 5108 99.06 6.43 
3. 150 7963 98.49 7.42 
4. 200 10397 98.72 7.67 
5. 250 13459 99.37 6.91 
*n = 6 (Mean of 6 values) for inter day studies    
 
Table 3     Accuracy and Precision Studies of pirfenidone (Intra day) 
 
Si.No 
Conc. of       
Drug (ng/ml) 
Mean* Peak 
Area 
Accuracy 
(%) 
Precision 
(%) 
1. 50 2409 98.65 5.64 
2. 100 5093 99.33 6.21 
3. 150 8221 98.72 6.54 
4. 
 
200 10426 98.64 5.94 
5. 250 13459 99.23 6.93 
*n = 6 (Mean of 6 values) for intraday studies    
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Linearity and rang : 
       According to ICH guidelines, the method proved to be linear between 50-250 
ng/mL for pirfenidone with a correlation equation  Y=54.97x- 349.5 and  correlation 
coefficient  R
2
 was 0.998 (fig.28).  
Limit of Detection and Limit of Quantification: 
        The limit of quantification (LOQ) and limit of detection (LOD) of pirfenidone 
was found to be 12 ng/ml and 20 ng/ml respectively . 
Recovery from plasma: 
       The extraction efficiency of pirfenidone from rat plasma at the concentrations of 
50, 100, and 200 ng/ml was found to be 97.72%, 99.01% and 99.11% with %RSD of 
8.2, 7.5, and 7.9. The results of recovery studies are shown in Table 4. 
 
Table 4  Recovery studies of pirfenidone 
Levels 
Conc. of Drug 
added 
(ng/ml) 
 
Amount of 
drug 
recovered in 
plasma sample 
(ng/ml) 
Relative 
Recovery 
(%) 
% RSD 
 
Level-I 50 48.86 97.72 8.2 
Level-II 100 99.01 99.01 7.5 
Level-III 150 148.67 99.11 7.9 
 
Ruggedness: 
   It expresses the precision within laboratory variations like different days, 
different analyst, and different equipments. Ruggedness of the method was assessed 
by spiking the standard six times in two different days with different analyst and the 
reports are shown in Table5. 
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Table 5   Ruggedness studies for pirfenidone 
Drug Concentration Mean * peak area %RSD 
Pirfenidone 100 ng mL
-1 Day I 
Analyst 1 
5169 0.51 
Pirfenidone 100ng mL
-1 Day II 
Analyst 2 
5237 0.68 
 *n=6 (Mean of 6 values) 
  
System suitability: 
       Column efficiency (theoretical plates), resolution factor and peak asymmetry 
factor, HETP, tailing factor, LOQ, LOD are the system suitability parameters. These 
parameters of the optimized methods were found satisfactory. The results of the 
system suitability studies in plasma were shown in table 6. These parameters were 
shown to be within specified limits. 
 
Table 6:  System suitability studies 
 
Si.No Parameters Pirfenidone 
1. Theoretical Plate 4792.42 
2. Tailing Factor 0.9523 
3. HETP 35.601 
4. LOD 12ng/ml 
5. LOQ 20ng/ml 
6. Resolution 4.658 
7. K 3.126 
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Pharmacokinetic Study  
           After a single oral dose of 30.0mg/kg of pirfenidone the sample was in 
measurable amount in plasma up to 2 h. The pharmacokinetic parameters of the 
samples were calculated using semilog graph, graph pad version 5, Microsoft excels 
software  and  the results were given in the Table 7 and 8  . 
            The maximum concentration (Cmax) obtained for pirfenidone before food and 
after food were found to be 1020.76 and 836.51 ng/ml respectively. The half life (t1/2) 
of pirfenidone  before food and after food were calculated and found to be 2.732158 h  
and4.009485 h. Area under the curve 
tAUC .0  of  pirfenidone  before food and after 
food were found to be   3060.95 and 2534.16 ng h/ml and 0AUC  was found to be 
3053.07 and   2510.64 ng h/ml.. Elimination rate constant (keli) was calculated for 
pirfenidone from the slope of log concentration versus time curve with regression 
analysis. Elimination rate constant for pirfenidone before food and after food were 
found to be   0.004228 and  0.002881  h
-1
. 
 
Table7: Plasma concentration of pirfenidone before food and after food 
 
Time  (h) 
Plasma Concentration( ng/ml) 
Before Food After Food 
0.5 236.42 204.19 
1.0 378.68 322.25 
2.0 960.76 836.51 
4.0 436.15 355.91 
6.0 314.47 274.84 
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Table8   :   Pharmacokinetic parameters of pirfenidone 
 
Si.No Parameters 
Pirfenidone 
Before food After food 
1 AUC 0-t (ng.h/ml) 3060.95 2534.16 
2 AUC 0-∞ (ng.h/ml) 3053.07 2510.64 
3 Cmax (ng/ml) 1020.76 836.51 
4 Tmax (h) 2.0 2.0 
5 KEli (h
-1
) 0.004228 0.002881 
6 t1/2 (h) 2.732158 4.009485 
 
  
 The pharmacokinetic parameters such as Cmax, Tmax, AUC 0-t, AUC 0-∞, 
KEli ,and  t1/2 were compared by statistical analysis. The p value obtained from t-test 
was found to be 0.3408.  As per above mentioned concentration, there is no 
significant difference in concentration of pirfenidone before and after food. 
 
 
 
 
Fig 29:  Comparison of plasma concentration of Pirfenidone before and after 
food 
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CHAPTER-8 
SUMMARY 
 
A rapid, sensitive and selective HPLC method for the determination of 
pirfenidone in rat plasma was developed and validated. Sample preparation was 
assured by protein precipitation method. Separation was occurred on a Phenomenex 
C-18 RP column (25 cm x 4.6 mm, 5µm ID) with a mobile phase Methanol and 
Acetonitrile: water pH 3.5 (40:60%v/v)  adjusted with orthophosphoric acid and was 
eluted at a flow rate of 1.0mL min
-1
 and the detection  was  done at 324 nm. 
          The standard curve was linear over the concentration range of 50-250 ng /ml. 
The limit of quantification (LOQ) and limit of detection (LOD) of Pirfenidone was 
found to be 12ng mL
-1
 and 20ng mL
-1 
respectively. The validation parameters of 
accuracy and precision study were performed at two levels such as intra-day and 
inter-day. The developed method shows good accuracy and precision. Accuracy 
ranges from 98.49% to 99.37% with the precision 6.43% to 7.67% in inter-day 
method. Intra-day method the accuracy ranges from 98.64% to 99.33% with the 
precision 5.64%   to 6.93 %.  This method was successfully applied to the 
bioavailability study of Pirfenidone.  
           For bioanalytical study, parameters like Cmax, Tmax, AUC 0-t, AUC 0-∞, Keli  and 
t1/2 were compared by statistical analysis. The maximum concentration (Cmax) 
obtained for pirfenidone before and after food was found to be 1020.76ng mL
-1
 and 
836.5 ng mL
-1
 respectively. The half life (t1/2) of pirfenidone before and after food 
were calculated and found to be  2.732158 h and 4.009485 h respectively. Area under 
the curve 
tAUC .0  of pirfenidone before food was calculated as 3060.95 ng h mL
-1
 and 

0AUC  was found to be 3053.07ng h mL
-1
. Area under the curve 
tAUC .0  of 
pirfenidone after food was calculated as 2534.16 ng h mL
-1
 and 

0AUC  was found to 
be 2510.64ng h mL
-1
. Elimination rate constant (keli) was calculated for pirfenidone 
from the slope of log concentration versus time curve with regression analysis. 
Elimination rate constant for Pirfenidone was found to be 0.004228 h
-1
 and 0.002881 
h
-1 
respectively. 
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CHAPTER-9 
CONCLUSION 
 
A bioanalytical method was developed and validated for pirfenidone. The 
effect of food on the concentration of pirfenidone in plasma was studied from the data 
acquired. 
The bioanalytical method developed was found to be simple, accurate, specific 
and reproducible. It can be used for the estimation of pirfenidone in plasma. The 
developed separation method gave acceptable values for recovery. Well resolved 
peaks were obtained for pirfenidone and internal standard (Tinidazole) without any 
interference. 
Pharmacokinetic  parameters such as Cmax, Tmax, AUC 0-t, AUC 0-∞, KEli ,and  
t1/2 were calculated and the statistical analysis indicates that there is no significant 
difference  in the pharmacokinetic profile of pirfenidone before and after food.  
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